Abeona Therapeutics (ABEO)

• Market cap: $324M
• 1 day: 3.64%
• 5 days: 10.06%
• 1 month: 6.55%
• 3 months: 11.13%
• 6 months: 12.23%
• Year to date: 7.16%
• 1 year: -7.03%
• 5 years: -86.21%
• 10 years: -93.02%
• Sector: Healthcare
• Industry: Biotechnology

About: Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

Employees: 226